Drug Database · Clinicians

Dabigatran etexilate

Brands (22) Dabicet, Gribero, Karisa…Show all

Direct thrombin inhibitor; Antithrombotic agent (direct thrombin inhibitor); and others PH FDA category

AF: 75 mg BID if CrCl 15–30Rx · Prescription drugOTC · Over-the-counter34 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, version date June 25, 2025 (Pradaxa · Boehringer Ingelheim Pharmaceuticals Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation
  • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days
  • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated
  • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery
  • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days
  • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE PRADAXA Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery (1.4) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days (1.5) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients PRADAXA Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery PRADAXA Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. 1.5 Treatment of Venous Thromboembolic Events in Pediatric Patients PRADAXA Capsules is indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days [see Dosage and Administration (2.3)]. 1.6 Reduction in the Risk of Recurrence of Venous Thromboembolic Events in Pediatric Patients PRADAXA Capsules is indicated to reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated [see Dosage and Administration (2.3)].

Contraindications

  • Active pathological bleeding
  • Serious hypersensitivity to dabigatran
  • Mechanical prosthetic heart valve
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS PRADAXA is contraindicated in patients with: Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)] History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions (6.1)] Mechanical prosthetic heart valve [see Warnings and Precautions (5.4)] Active pathological bleeding (4) History of serious hypersensitivity reaction to PRADAXA (4) Mechanical prosthetic heart valve (4)

Dosing: Adult

  • Nonvalvular atrial fibrillation: CrCl >30: 150 mg twice daily; CrCl 15–30: 75 mg twice daily
  • DVT/PE treatment and prevention of recurrence: 150 mg twice daily (CrCl >30), after 5 to 10 days of parenteral anticoagulation for treatment
  • Prophylaxis after hip replacement: 110 mg on day 1, then 220 mg once daily (CrCl >30)
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Non-valvular Atrial Fibrillation in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily (2.2)
  • For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily (2.2)
  • Treatment of DVT and PE in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation (2.2)
  • Reduction in the Risk of Recurrence of DVT and PE in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after previous treatment (2.2)
  • Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients: For patients with CrCl > 30 mL/min: 110 mg orally first day, then 220 mg once daily (2.2)
  • Treatment of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after at least 5 days of parenteral anticoagulant (2.3)
  • Reduction in the Risk of Recurrence of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after previous treatment (2.3)
  • Pradaxa Capsules are NOT substitutable on a milligram-to-milligram basis with other dabigatran etexilate dosage forms Review recommendations for converting to or from other oral or parenteral anticoagulants (2.6, 2.7)
  • Temporarily discontinue PRADAXA before invasive or surgical procedures when possible, then restart promptly (2.8)
2.1 Important Dosage Information

2.1 Important Dosage Information Dabigatran etexilate is available in different dosage forms and not all dosage forms are approved for the same indications and age groups. In addition, there are differences between the dosage forms with respect to dosing due to differences in bioavailability. Do not substitute different dosage forms on a milligram-to-milligram basis and do not combine more than one dosage form to achieve the total dose [see Clinical Pharmacology (12.3)].

2.2 Recommended

2.2 Recommended PRADAXA Capsules Dosage for Adults Indication Dosage Reduction in Risk of Stroke and Systemic Embolism in Non-valvular AF CrCl > 30 mL/min: 150 mg twice daily CrCl 15 to 30 mL/min: 75 mg twice daily CrCl < 15 mL/min or on dialysis: Dosing recommendations cannot be provided CrCl 30 to 50 mL/min with concomitant use of P-gp inhibitors: Reduce dosage to 75 mg twice daily if given with P-gp inhibitors dronedarone or systemic ketoconazole. CrCl < 30 mL/min with concomitant use of P-gp inhibitors: Avoid coadministration Treatment of DVT and PE CrCl > 30 mL/min: 150 mg twice daily Reduction in the Risk of Recurrence of DVT and PE CrCl ≤ 30 mL/min or on dialysis: Dosing recommendations cannot be provided CrCl < 50 mL/min with concomitant use of P-gp inhibitors: Avoid coadministration Prophylaxis of DVT and PE Following Hip Replacement Surgery CrCl > 30 mL/min: 110 mg for first day, then 220 mg once daily CrCl ≤ 30 mL/min or on dialysis: Dosing recommendations cannot be provided CrCl < 50 mL/min with concomitant use of P-gp inhibitors: Avoid coadministration Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients For patients with creatinine clearance (CrCl) > 30 mL/min, the recommended dosage of PRADAXA Capsules is 150 mg taken orally, twice daily.

For patients with severe renal impairment (CrCl 15-30 mL/min), the recommended dosage of PRADAXA Capsules is 75 mg twice daily [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. Dosing recommendations for patients with a CrCl < 15 mL/min or on dialysis cannot be provided. Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients For patients with CrCl > 30 mL/min, the recommended dosage of PRADAXA Capsules is 150 mg taken orally, twice daily, after 5-10 days of parenteral anticoagulation.

Dosing recommendations for patients with a CrCl ≤ 30 mL/min or on dialysis cannot be provided [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients For patients with CrCl > 30 mL/min, the recommended dosage of PRADAXA Capsules is 150 mg taken orally, twice daily after previous treatment.

Dosing recommendations for patients with a CrCl ≤ 30 mL/min or on dialysis cannot be provided [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery For patients with CrCl > 30 mL/min, the recommended dosage of PRADAXA Capsules is 110 mg taken orally 1-4 hours after surgery and after hemostasis has been achieved, then 220 mg taken once daily for 28-35 days.

If PRADAXA is not started on the day of surgery, after hemostasis has been achieved initiate treatment with 220 mg once daily. Dosing recommendations for patients with a CrCl ≤ 30 mL/min or on dialysis cannot be provided [see Dosage and Administration (2.4), Use in Specific Populations (8.6), and Clinical Pharmacology (12.2, 12.3)].

2.3 Recommended

2.3 Recommended PRADAXA Capsules Dosage for Pediatrics PRADAXA Capsules can be used in pediatric patients aged 8 to less than 18 years of age who are able to swallow the capsules whole. Other age-appropriate pediatric dosage forms of dabigatran etexilate are available for pediatric patients less than 8 years of age. For the treatment of VTE in pediatric patients, initiate treatment following treatment with a parenteral anticoagulant for at least 5 days.

For reduction in risk of recurrence of VTE, initiate treatment following previous treatment. PRADAXA Capsules is dosed orally twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible. The recommended dosage of PRADAXA Capsules for the treatment of or reducing the risk of VTE in pediatric patients 8 to less than 18 years of age is based on the patient's actual weight as shown in Table 1 below.

Administer PRADAXA twice daily. Adjust the dosage according to actual weight as treatment progresses [see Dosage and Administration (2.5)]. Table 1 Weight-Based PRADAXA Capsules Dosage for Pediatric Patients Aged 8 to Less Than 18 Years Actual Weight (kg) Dosage (mg) Number of Capsules Needed 11 kg to less than 16 kg 75 mg twice daily one 75 mg capsule twice daily 16 kg to less than 26 kg 110 mg twice daily one 110 mg capsule twice daily 26 kg to less than 41 kg 150 mg twice daily one 150 mg capsule twice daily or two 75 mg capsules twice daily 41 kg to less than 61 kg 185 mg twice daily one 110 mg capsule plus one 75 mg capsule twice daily 61 kg to less than 81 kg 220 mg twice daily two 110 mg capsule twice daily 81 kg or greater 260 mg twice daily one 150 mg capsule plus one 110 mg capsule twice daily or one 110 mg capsule plus two 75 mg capsules twice daily

2.4 Dosage Adjustments

2.4 Dosage Adjustments Adult patients with renal impairment Assess renal function prior to initiation of treatment with PRADAXA Capsules. Periodically assess renal function as clinically indicated (i.e., more frequently in clinical situations that may be associated with a decline in renal function) and adjust therapy accordingly.

Discontinue PRADAXA in patients who develop acute renal failure while on PRADAXA and consider alternative anticoagulant therapy. Generally, in adult patients, the extent of anticoagulation does not need to be assessed. When necessary, use aPTT or ECT, and not INR, to assess for anticoagulant activity in adult patients on PRADAXA Capsules [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.2)].

Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation In patients with moderate renal impairment (CrCl 30-50 mL/min), concomitant use of the P-gp inhibitor dronedarone or systemic ketoconazole can be expected to produce dabigatran exposure similar to that observed in severe renal impairment. Reduce the dosage of PRADAXA Capsules to 75 mg twice daily [see Warnings and Precautions (5.5), Drug Interactions (7.1), and Clinical Pharmacology (12.3)].

Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Dosing recommendations for patients with CrCl ≤ 30 mL/min cannot be provided. Avoid use of concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Warnings and Precautions (5.5), Drug Interactions (7.2) and Clinical Pharmacology (12.3)].

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery Dosing recommendations for patients with CrCl ≤ 30 mL/min or on dialysis cannot be provided. Avoid use of concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Dosage and Administration (2.5), Warnings and Precautions (5.5), Drug Interactions (7.3), and Clinical Pharmacology (12.2, 12.3)].

Pediatric patients with renal impairment Treatment and reduction in risk of recurrence of VTE in pediatric patients Due to lack of data in pediatric patients with eGFR < 50 mL/min/1.73 m² and the risk of increased exposure, avoid use of PRADAXA Capsules in these patients. Prior to the initiation of treatment with PRADAXA Capsules, estimate the glomerular filtration rate (eGFR) using the Schwartz formula: eGFR (Schwartz) = (0.413 × height in cm) / serum creatinine in mg/dL.

Treat patients with an eGFR > 50 mL/min/1.73 m² with the dosage according to Table 1 [see Dosage and Administration (2.3)].

2.5 Administration

2.5 Administration PRADAXA Capsules should be swallowed whole. PRADAXA Capsules should be taken with a full glass of water. Breaking, chewing, or emptying the contents of the capsule can result in increased exposure [see Clinical Pharmacology (12.3)]. If a dose of PRADAXA Capsules is not taken at the scheduled time, the dose should be taken as soon as possible on the same day; the missed dose should be skipped if it cannot be taken at least 6 hours before the next scheduled dose.

The dose of PRADAXA Capsules should not be doubled to make up for a missed dose. Consider administration with food if gastrointestinal distress occurs with PRADAXA Capsules.

2.6 Converting from or to Warfarin

2.6 Converting from or to Warfarin When converting patients from warfarin therapy to PRADAXA Capsules, discontinue warfarin and start PRADAXA Capsules when the INR is below 2.0. When converting from PRADAXA Capsules to warfarin, adjust the starting time of warfarin as follows: Adults For CrCl ≥ 50 mL/min, start warfarin 3 days before discontinuing PRADAXA Capsules.

For CrCl 30-50 mL/min, start warfarin 2 days before discontinuing PRADAXA Capsules. For CrCl 15-30 mL/min, start warfarin 1 day before discontinuing PRADAXA Capsules. For CrCl < 15 mL/min, no recommendations can be made. Pediatrics For eGFR ≥ 50 mL/min/1.73 m², start warfarin 3 days before discontinuing PRADAXA Capsules. Pediatric patients with an eGFR < 50 mL/min/1.73 m² have not been studied.

Avoid use of PRADAXA Capsules in these patients. Because PRADAXA Capsules can increase INR, the INR will better reflect warfarin's effect only after PRADAXA Capsules has been stopped for at least 2 days [see Clinical Pharmacology (12.2)].

2.7 Converting from or to Parenteral Anticoagulants

2.7 Converting from or to Parenteral Anticoagulants For adult and pediatric patients currently receiving a parenteral anticoagulant, start PRADAXA Capsules 0 to 2 hours before the time that the next dose of the parenteral drug was to have been administered or at the time of discontinuation of a continuously administered parenteral drug (e.g., intravenous unfractionated heparin). For adult patients currently taking PRADAXA Capsules wait 12 hours (CrCl ≥ 30 mL/min) or 24 hours (CrCl < 30 mL/min) after the last dose of PRADAXA Capsules before initiating treatment with a parenteral anticoagulant [see Clinical Pharmacology (12.3)].

For pediatric patients currently taking PRADAXA, wait 12 hours after the last dose before switching to a parenteral anticoagulant.

2.8 Discontinuation for Surgery and Other Interventions

2.8 Discontinuation for Surgery and Other Interventions If possible, discontinue PRADAXA Capsules in adults 1 to 2 days (CrCl ≥ 50 mL/min) or 3 to 5 days (CrCl < 50 mL/min) before invasive or surgical procedures because of the increased risk of bleeding. Consider longer times for patients undergoing major surgery, spinal puncture, or placement of a spinal or epidural catheter or port, in whom complete hemostasis may be required [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

For pediatric patients, discontinue PRADAXA Capsules 24 hours before an elective surgery (eGFR > 80 mL/min/1.73 m²) or 2 days before an elective surgery (eGFR 50-80 mL/min/1.73 m²). Pediatric patients with an eGFR <50 mL/min/1.73 m² have not been studied, avoid use of PRADAXA Capsules in these patients. If surgery cannot be delayed, there is an increased risk of bleeding [see Warnings and Precautions (5.2)].

This risk of bleeding should be weighed against the urgency of intervention [see Warnings and Precautions (5.1, 5.3)]. Use a specific reversal agent (idarucizumab) in case of emergency surgery or urgent procedures when reversal of the anticoagulant effect of dabigatran is needed in adults. Efficacy and safety of idarucizumab have not been established in pediatric patients [see Warnings and Precautions (5.2)].

Refer to the idarucizumab prescribing information for additional information. Restart PRADAXA Capsules as soon as medically appropriate.

Dosing: Altered kidney function

Dabigatran is a direct thrombin inhibitor cleared about 80% by the kidneys, so exposure rises steeply as kidney function falls (AUC 3.2-fold at CrCl 30–50 and 6.3-fold at 15–30). The US label uses 150 mg twice daily above CrCl 30 and 75 mg twice daily at 15–30 for atrial fibrillation, and gives no dose below 15 or on dialysis. For venous thromboembolism it gives no dose at CrCl 30 or below. It is dialyzable.

Kidney function measure: Label uses Cockcroft-Gault CrCl (mL/min): >30, 15–30, <15; P-gp inhibitor limits at 30–50 and <50.

Show full dosing details
CrCl ≥60 mL/min
Atrial fibrillation (AF): 150 mg twice daily. VTE treatment or prevention of recurrence: 150 mg twice daily (after 5 to 10 days of parenteral anticoagulation for treatment). Hip-replacement prophylaxis: 110 mg on day 1, then 220 mg once daily (label).
CrCl 30–59 mL/min
CrCl >30: usual doses. With P-gp inhibitors: AF at CrCl 30–50 with dronedarone or systemic ketoconazole, 75 mg twice daily; VTE indications at CrCl <50, avoid P-gp inhibitors (label).
CrCl 15–29 mL/min
AF, CrCl 15–30: 75 mg twice daily; avoid P-gp inhibitors (label). VTE indications at CrCl ≤30: dosing cannot be provided. This dose is based on pharmacokinetic modeling; CrCl <30 was not studied in RE-LY (label 12.3). PH registers 75 mg capsules.
CrCl <15 mL/min (not on dialysis)
AF at CrCl <15: dosing recommendations cannot be provided (label). Site position (not label wording): avoid; exposure rises steeply (AUC 6.3-fold at CrCl 15–30, label 12.3), and in hemodialysis patients with AF dabigatran was associated with more bleeding than warfarin (Chan 2015). Choose another anticoagulant.
Hemodialysis (intermittent)
Dosing recommendations cannot be provided (label): CrCl <15 or dialysis for atrial fibrillation; CrCl ≤30 or dialysis for VTE treatment, prevention of recurrence and hip-replacement prophylaxis. Hemodialysis removes about 49% to 57% over 4 hours (label 10). In hemodialysis patients with AF, dabigatran was associated with more hospitalization or death from bleeding than warfarin (rate ratio 1.48) and more hemorrhagic death (rate ratio 1.78) (Chan 2015); choose another anticoagulant. The red tile is a site position, not label wording.
Peritoneal dialysis
No dose in label (dialysis): dosing recommendations cannot be provided. Site position (not label wording): avoid, as on hemodialysis (Chan 2015); choose another anticoagulant.
CRRT
No dose in label. Site position (not label wording): avoid; exposure rises steeply as kidney function falls (label 12.3). Use another anticoagulant.
  • Dialyzable? Yes: high-flux hemodialysis removed about 49% over 4 hours (blood flow 200 mL/min) to 57% (300 mL/min), with 7% to 15% rebound; protein binding about 35% (label 10).
  • Monitoring CrCl before starting and when kidney function may decline (e.g., hypovolemia, nephrotoxic drugs); stop if acute kidney injury. Bleeding, hemoglobin. Reversal: idarucizumab in adults; hemodialysis has limited supporting data. Before surgery or invasive procedures, stop 1 to 2 days ahead if CrCl ≥50 mL/min, 3 to 5 days if CrCl <50; longer for major surgery or spinal/epidural procedures (label 2.8).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
eGFR >50: weight-based dose (label).
eGFR 30–59
eGFR >50: weight-based dose. eGFR <50: avoid (no data, higher exposure; label 2.4).
eGFR 15–29
Avoid: eGFR <50 (label).
eGFR <15 (not on dialysis)
Avoid: eGFR <50 (label).
Hemodialysis (intermittent)
Avoid (eGFR <50; label).
Peritoneal dialysis
Avoid (eGFR <50; label).
CRRT
Avoid (eGFR <50; label).

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

8.6 Renal Impairment Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients No dose adjustment of PRADAXA is recommended in patients with mild or moderate renal impairment [see Clinical Pharmacology (12.3)]. Reduce the dose of PRADAXA in patients with severe renal impairment (CrCl 15-30 mL/min) [see Dosage and Administration (2.2, 2.4) and Clinical Pharmacology (12.3)].

Dosing recommendations for patients with CrCl < 15 mL/min or on dialysis cannot be provided. Adjust dose appropriately in patients with renal impairment receiving concomitant P-gp inhibitors [see Warnings and Precautions (5.5), Drug Interactions (7.1), and Clinical Pharmacology (12.3)]. Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Patients with severe renal impairment (CrCl ≤ 30 mL/min) were excluded from RE-COVER.

Dosing recommendations for patients with CrCl ≤ 30 mL/min or on dialysis cannot be provided. Avoid use of PRADAXA with concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Warnings and Precautions (5.5), Drug Interactions (7.2), and Clinical Pharmacology (12.3)]. Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Patients with severe renal impairment (CrCl < 30 mL/min) were excluded from RE-NOVATE and RE-NOVATE II.

Dosing recommendations for patients with CrCl < 30 mL/min or on dialysis cannot be provided. Avoid use of PRADAXA with concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Warnings and Precautions (5.5), Drug Interactions (7.3), and Clinical Pharmacology (12.2, 12.3)]. Treatment and Reduction in the Risk of Recurrence of VTE in Pediatric Patients PRADAXA has not been studied in pediatric patients with eGFR < 50 mL/min/1.73 m².

Reduced renal function could increase exposure. Dosing recommendations cannot be provided for treatment of these patients. Avoid use of PRADAXA Capsules in these patients [see Dosage and Administration (2.4)].

Renal Impairment An open, parallel-group, single-center study compared dabigatran pharmacokinetics in healthy adult subjects and adult patients with mild to moderate renal impairment receiving a single dose of PRADAXA Capsules 150 mg. Exposure to dabigatran increases with severity of renal function impairment (Table 10).

Similar findings were observed in the RE-LY, RE-COVER and RE-NOVATE II trials. Table 10 Impact of Renal Impairment on Dabigatran Pharmacokinetics Renal Function CrCl (mL/min) Increase in AUC Increase in C max t 1/2 (h) + Patients with severe renal impairment were not studied in RE-LY, RE-COVER and RE-NOVATE II. Dosing recommendations in subjects with severe renal impairment are based on pharmacokinetic modeling [see Dosage and Administration (2.2, 2.4) and Use in Specific Populations (8.6)].

Normal ≥ 80 1× 1× 13 Mild 50-80 1.5× 1.1× 15 Moderate 30-50 3.2× 1.7× 18 Severe + 15-30 6.3× 2.1× 27 Hepatic Impairment Administration of PRADAXA Capsules in adult patients with moderate hepatic impairment (Child-Pugh B) showed a large inter-subject variability, but no evidence of a consistent change in exposure or pharmacodynamics.

Dosing: Pediatric

Approved ages
VTE treatment and prevention of recurrence, 8 to <18 years (capsules); other dabigatran dosage forms for under 8 years (label).
Usual dose
Weight-based twice daily (label Table 1): 11 to <16 kg, 75 mg; 16 to <26 kg, 110 mg; 26 to <41 kg, 150 mg; 41 to <61 kg, 185 mg; 61 to <81 kg, 220 mg; 81 kg or more, 260 mg.
Maximum dose
260 mg twice daily (81 kg or more).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of PRADAXA Capsules for the treatment and the reduction in risk of recurrence of venous thromboembolism have been established in pediatric patients 8 to less than 18 years of age. Use of PRADAXA for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients.

These studies included an open-label, randomized, parallel-group study and an open-label, single-arm safety study [see Adverse Reactions (6.1) and Clinical Studies (14.4, 14.5)]. Other age-appropriate pediatric dosage forms of dabigatran etexilate are available for pediatric patients less than 8 years of age for these indications.

Safety and effectiveness of PRADAXA Capsules have not been established in pediatric patients with non-valvular atrial fibrillation or those who have undergone hip replacement surgery.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of patients in the RE-LY study, 82% were 65 and over, while 40% were 75 and over. The risk of stroke and bleeding increases with age, but the risk-benefit profile is favorable in all age groups [see Warnings and Precautions (5), Adverse Reactions (6.1), and Clinical Studies (14.1)].

Administration

2.5 Administration PRADAXA Capsules should be swallowed whole. PRADAXA Capsules should be taken with a full glass of water. Breaking, chewing, or emptying the contents of the capsule can result in increased exposure [see Clinical Pharmacology (12.3) ] . If a dose of PRADAXA Capsules is not taken at the scheduled time, the dose should be taken as soon as possible on the same day; the missed dose should be skipped if it cannot be taken at least 6 hours before the next scheduled dose. The dose of PRADAXA Capsules should not be doubled to make up for a missed dose. Consider administration with food if gastrointestinal distress occurs with PRADAXA Capsules.

US FDA label

Dosage forms

Philippines

  • Capsule: 75 mg, 110 mg, 150 mg

Registered products in the Philippines

34 products registered with the Food and Drug Administration (FDA) Philippines list Dabigatran etexilate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products34
Philippine FDA-registered products for Dabigatran etexilate
Package insert
Amgathran-110Dabigatran Etexilate (as mesilate)
110 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-14441-02
Sep 5, 2028
Amgathran-150Dabigatran Etexilate (as mesilate)
150 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-14440-01
Sep 5, 2028
Amgathran-75Dabigatran Etexilate (as mesilate)
75 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-14442-01
Sep 5, 2028
Dabbtrann-110Dabigatran Etexilate (as mesilate)
110 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-14441-01
Sep 5, 2028
Dabbtrann-150Dabigatran Etexilate (as mesilate)
150 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-14440-02
Sep 5, 2028
Dabbtrann-75Dabigatran Etexilate (as mesilate)
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-14442-02
Sep 5, 2028
Dabexa 110Dabigatran etexilate (as mesylate)
110mg CapsulesAlu/Alu Blister Pack x 10's (Box of 30’s & 60’s)
Rx
Zim Laboratories LimitedIndia
Medethix, Inc.
DR-XY49781
Aug 11, 2031
Dabexa 150Dabigatran etexilate (as mesylate)
150mg CapsulesAlu/Alu Blister Pack x 10's (Box of 30’s & 60’s)
Rx
Zim Laboratories LimitedIndia
Medethix, Inc.
DR-XY49780
Aug 11, 2031
DabicetDabigatran Etexilate (as mesylate)
110 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14621
Nov 14, 2028
DabicetDabigatran Etexilate (as mesylate)
150 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14620
Nov 14, 2028
DabicetDabigatran Etexilate (as mesylate)
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14622
Nov 14, 2028
DabiqxDabigatran Etexilate (as mesilate)
110 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Trader: N/A
DR-XY49676
Mar 19, 2031
DabiqxDabigatran Etexilate (as mesilate)
150 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc
DRP-16488
Mar 27, 2030
Dabitrin 110Dabigatran etexilate (as mesilate)
110 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DRP-16486
Mar 25, 2030
Dabitrin 110Dabigatran Etexilate (as mesylate)
110 mg CapsuleWhite opaque HDPE container with child-resistant plastic cap containing 60 capsules (Box of 60's)
Rx
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DRP-16766
Jul 9, 2030
Dabitrin 150Dabigatran etexilate (as mesilate)
150 mg CapsuleAlu/Alu blister pack x 10's (Box of 30's)
Rx
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DR-XY48157
Mar 14, 2029
Dabitrin 75Dabigatran etexilate (as mesilate)
75 mg CapsuleAlu/Alu blister pack x 10's (Box of 30's)
Rx
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DR-XY48158
Mar 14, 2029
GriberoDabigatran Etexilate (as mesylate)
110 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
MSN Laboratories Private LimitedIndia
Sandoz Philippines Corporation
DRP-12359
Jul 25, 2027
GriberoDabigatran etexilate (as mesylate)
150 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
MSN Laboratories Private Limited Formulations DivisionIndia
Sandoz Philippines Corporation
DRP-11554
Mar 29, 2027
GriberoDabigatran Etexilate (as mesylate)
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
MSN Laboratories Private LimitedIndia
Sandoz Philippines Corporation
DRP-12360
Jul 25, 2027
KarisaDabigatran Etexilate (as mesylate)
110 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Globela Pharma Private LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-14621-01
Nov 14, 2028
KarisaDabigatran Etexilate (as mesylate)
150 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Globela Pharma Private LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-14620-01
Nov 14, 2028
KarisaDabigatran Etexilate (as mesylate)
75 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Globela Pharma Private LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-14622-01
Nov 14, 2028
Khrizdaxa 150Dabigatran Etexilate (as mesilate)
150mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Pell Tech Health Care Pvt. Ltd.India
Khriz Pharma Trading Inc.
DRP-18069
Apr 30, 2031
NoneDabigatran Etexilate (as mesylate)
110mg CapsulesAlu/Alu Blister Pack x 10's (Box of 30's & 60's)
Rx
Zim Laboratories LimitedIndia
Medethix, Inc.
DR-XY49785
Aug 11, 2031
PradaxaDabigatran Etexilate
110 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7436
Jan 30, 2029
PradaxaDabigatran Etexilate (as mesilate)
150 mg CapsuleAlu-Alu Blister Pack x 10's (Box of 30's)
Rx
Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Boehringer Ingelheim (Philippines), Inc.
DRP-7438
Mar 23, 2031
PradaxaDabigatran Etexilate
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7435
Jan 30, 2029
Pulgatran 75Dabigatran Etexilate
75 mg CapsuleAlu-Alu Blisterpack x 10’s (Box of 30’s, 60’s and 100’s)
Rx
Simpex Pharma Pvt. Ltd.India
Despina Pharma Inc.
DRP-18904
Sep 29, 2031
Stabigran 110Dabigatran Etexilate (as mesilate)
110 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International CorporationTrader: N/A
DRP-14441
Sep 5, 2028
Stabigran 150Dabigatran Etexilate (as mesilate)
150 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International CorporationTrader: N/A
DRP-14440
Sep 5, 2028
Stabigran 75Dabigatran Etexilate (as mesilate)
75 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
OTC
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation.Importer: Ambica International CorporationTrader: N/A
DRP-14442
Sep 5, 2028
TravixaDabigatran Etexilate (as mesilate)
110 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Aspen Philippines Inc.Importer: Ambica International Corporation
DRP-14441-03
Sep 5, 2028
TravixaDabigatran Etexilate (as mesilate)
150 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Aspen Philippines Inc.Importer: Ambica International Corporation
DRP-14440-03
Sep 5, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 150 mg capsules with a light blue opaque cap imprinted in black with the Boehringer Ingelheim company symbol and a white opaque body imprinted in black with "R150". 110 mg capsules with a light blue opaque cap imprinted in black with the Boehringer Ingelheim company symbol and a light blue opaque body imprinted in black with "R110". 75 mg capsules with a white opaque cap imprinted in black with the Boehringer Ingelheim company symbol and a white opaque body imprinted in black with "R75". Capsules: 75 mg, 110 mg and 150 mg (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Bleeding: PRADAXA can cause serious and fatal bleeding (5.2)
  • Bioprosthetic heart valves: PRADAXA use not recommended (5.4)
  • Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome: PRADAXA use not recommended (5.6)
5.1 Increased Risk of Thrombotic

5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including PRADAXA, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If PRADAXA Capsules is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant and restart PRADAXA Capsules as soon as medically appropriate [see Dosage and Administration (2.6, 2.7, 2.8)].

5.2 Risk of Bleeding

5.2 Risk of Bleeding PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA Capsules in patients with active pathological bleeding [see Dosage and Administration (2.4)].

Risk factors for bleeding include the concomitant use of other drugs that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment [see Clinical Pharmacology (12.2)].

Reversal of Anticoagulant Effect In adults, a specific reversal agent (idarucizumab) for PRADAXA is available when reversal of the anticoagulant effect of dabigatran is needed: For emergency surgery/urgent procedures In life-threatening or uncontrolled bleeding In pediatric patients, the efficacy and safety of idarucizumab have not been established. Hemodialysis can remove dabigatran; however the clinical experience supporting the use of hemodialysis as a treatment for bleeding is limited [see Overdosage (10)].

Prothrombin complex concentrates, or recombinant Factor VIIa may be considered but their use has not been evaluated in clinical trials. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. Consider administration of platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet drugs have been used.

5.3 Spinal/Epidural Anesthesia or Puncture

5.3 Spinal/Epidural Anesthesia or Puncture When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see Boxed Warning]. To reduce the potential risk of bleeding associated with the concurrent use of PRADAXA and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of dabigatran [see Clinical Pharmacology (12.3)].

Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of dabigatran is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), bowel and/or bladder dysfunction.

Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.

5.4 Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves

5.4 Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves The safety and efficacy of PRADAXA Capsules in adult patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose-adjusted warfarin or 150 mg, 220 mg, or 300 mg of PRADAXA Capsules twice a day. RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA Capsules treatment arm as compared to the warfarin treatment arm.

These bleeding and thromboembolic events were seen both in patients who were initiated on PRADAXA Capsules postoperatively within three days of mechanical bileaflet valve implantation, as well as in patients whose valves had been implanted more than three months prior to enrollment. Therefore, the use of PRADAXA is contraindicated in all patients with mechanical prosthetic valves [see Contraindications (4)].

The use of PRADAXA for the prophylaxis of thromboembolic events in patients with atrial fibrillation in the setting of other forms of valvular heart disease, including the presence of a bioprosthetic heart valve, has not been studied and is not recommended.

5.5 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure

5.5 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3)]. P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran [see Clinical Pharmacology (12.3)].

Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Reduce the dosage of PRADAXA Capsules to 75 mg twice daily when dronedarone or systemic ketoconazole is co-administered with PRADAXA Capsules in patients with moderate renal impairment (CrCl 30-50 mL/min).

Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6)]. Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Avoid use of PRADAXA Capsules and concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Drug Interactions (7.2) and Use in Specific Populations (8.6)].

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Avoid use of PRADAXA Capsules and concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Drug Interactions (7.3) and Use in Specific Populations (8.6)]. Treatment and reduction in risk of recurrence of VTE in pediatric patients The concomitant use of PRADAXA Capsules with P-gp-inhibitors has not been studied in pediatric patients but may increase exposure to dabigatran.

5.6 Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome

5.6 Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome Direct-acting oral anticoagulants (DOACs), including PRADAXA, are not recommended for use in patients with triple-positive antiphospholipid syndrome (APS). For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

Drug interactions

Drug or classSeverityEffectWhat to do
P-gp inducers (rifampin)AvoidLower dabigatran exposure (label).Avoid.
P-gp inhibitors (dronedarone, systemic ketoconazole)Adjust or monitorHigher exposure, especially with kidney impairment (label).AF, CrCl 30–50: 75 mg twice daily; CrCl <30: avoid; VTE, CrCl <50: avoid.
Antiplatelets, NSAIDs, heparin, fibrinolytics, other anticoagulantsAdjust or monitorMore bleeding (label).Avoid unnecessary combinations; watch for bleeding.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • P-gp inducers: Avoid coadministration with PRADAXA (5.5)
  • P-gp inhibitors in adult patients with CrCl 30-50 mL/min: Reduce dosage or avoid (7) P-gp inhibitors in adult patients with CrCl < 30 mL/min: Not recommended (7)
7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in…

7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3)]. P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran [see Clinical Pharmacology (12.3)].

Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. In patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dosage of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole.

The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dosage adjustment of PRADAXA. These results should not be extrapolated to other P-gp inhibitors [see Warnings and Precautions (5.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)]. The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided [see Warnings and Precautions (5.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].

7.2 Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary

7.2 Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Avoid use of PRADAXA and P-gp inhibitors in patients with CrCl < 50 mL/min [see Warnings and Precautions (5.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].

7.3 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following…

7.3 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery In patients with CrCl ≥ 50 mL/min who have concomitant administration of P-gp inhibitors such as dronedarone or systemic ketoconazole, it may be helpful to separate the timing of administration of PRADAXA and the P-gp inhibitor by several hours. The concomitant use of PRADAXA and P-gp inhibitors in patients with CrCl < 50 mL/min should be avoided [see Warnings and Precautions (5.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.2, 12.3)].

7.4 Treatment and Reduction in Risk of Recurrence of VTE in Pediatric Patients

7.4 Treatment and Reduction in Risk of Recurrence of VTE in Pediatric Patients The concomitant use of PRADAXA with P-gp inhibitors has not been studied in pediatric patients but may increase exposure to dabigatran [see Warnings and Precautions (5.5)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Dabigatran etexilate is a substrate of the efflux transporter P-gp.

Dabigatran is not a substrate, inhibitor, or inducer of CYP450 enzymes.

In the orthopedic hip surgery patients, limited clinical data with P-gp inhibitors is available.

Figure 3.1 Effect of P-gp Inhibitor or Inducer (rifampicin) Drugs on Peak and Total Exposure to Dabigatran (C max and AUC).

The Perpetrator and Dabigatran Etexilate Dosage and Dosage Frequency are given as well as the Time of Perpetrator Dosage in Relation to Dabigatran Etexilate Dosage (Time Difference) Figure 3.2 Effect of Non-P-gp Inhibitor or Inducer, Other Drugs, on Peak and Total Exposure to Dabigatran (C max and AUC).

Figure 3.1 Figure 3.2 Impact of Dabigatran on Other Drugs In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.

7 DRUG INTERACTIONS P-gp inducers: Avoid coadministration with PRADAXA ( 5.5 ) P-gp inhibitors in adult patients with CrCl 30-50 mL/min: Reduce dosage or avoid ( 7 ) P-gp inhibitors in adult patients with CrCl < 30 mL/min: Not recommended ( 7 ) 7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3) ] .

P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran [see Clinical Pharmacology (12.3) ] .

Adverse reactions

Common

  • Dyspepsia, gastritis-like symptoms, nausea, upper abdominal pain
  • Bleeding

Serious

  • Major or fatal bleeding
  • Thrombotic events after premature discontinuation (boxed warning)
  • Spinal or epidural hematoma with neuraxial procedures (boxed warning)
  • Thrombosis with mechanical heart valves or triple-positive antiphospholipid syndrome
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Increased Risk of Thrombotic Events after Premature Discontinuation [see Warnings and Precautions (5.1)] Risk of Bleeding [see Warnings and Precautions (5.2)] Spinal/Epidural Anesthesia or Puncture [see Warnings and Precautions (5.3)] Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves [see Warnings and Precautions (5.4)] Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome [see Warnings and Precautions (5.6)] The most serious adverse reactions reported with PRADAXA were related to bleeding [see Warnings and Precautions (5.2)]. Most common adverse reactions (> 15%) are gastrointestinal adverse reactions and bleeding (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Trials Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation The RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) study provided safety information on the use of two doses of PRADAXA Capsules and warfarin [see Clinical Studies (14.1)].

The numbers of patients and their exposures are described in Table 2. Limited information is presented on the 110 mg dosing arm because this dose is not approved. Table 2 Summary of Treatment Exposure in RE-LY PRADAXA Capsules 110 mg twice daily PRADAXA Capsules 150 mg twice daily Warfarin Total number treated 5,983 6,059 5,998 Exposure > 12 months 4,936 4,939 5,193 > 24 months 2,387 2,405 2,470 Mean exposure (months) 20.5 20.3 21.3 Total patient-years 10,242 10,261 10,659 Drug Discontinuation in RE-LY The rates of adverse reactions leading to treatment discontinuation were 21% for PRADAXA Capsules 150 mg and 16% for warfarin.

The most frequent adverse reactions leading to discontinuation of PRADAXA Capsules were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea). Bleeding [see Warnings and Precautions (5.2)] Table 3 shows the number of adjudicated major bleeding events during the treatment period in the RE-LY study, with the bleeding rate per 100 subject-years (%).

Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of ≥ 2 g/dL, a transfusion of ≥ 2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome. Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.

Table 3 Adjudicated Major Bleeding Events in Treated Patients a Event PRADAXA Capsules 150 mg N = 6,059 n (%/year b) Warfarin N = 5,998 n (%/year b) PRADAXA Capsules 150 mg vs Warfarin HR (95% CI) a Patients during treatment or within 2 days of stopping study treatment. Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. b Annual event rate per 100 pt-years = 100 * number of subjects with event/subject-years.

Subject-years is defined as cumulative number of days from first drug intake to event date, date of last drug intake + 2, death date (whatever occurred first) across all treated subjects divided by 365.25. In case of recurrent events of the same category, the first event was considered. c Defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of ≥ 2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome. d Intracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds. e On-treatment analysis based on the safety population, compared to ITT analysis presented in Section 14 Clinical Studies. f Fatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding. g Non-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.

Major Bleeding c 350 (3.47) 374 (3.58) 0.97 (0.84, 1.12) Intracranial Hemorrhage (ICH) d 23 (0.22) 82 (0.77) 0.29 (0.18, 0.46) Hemorrhagic Stroke e 6 (0.06) 40 (0.37) 0.16 (0.07, 0.37) Other ICH 17 (0.17) 46 (0.43) 0.38 (0.22, 0.67) Gastrointestinal 162 (1.59) 111 (1.05) 1.51 (1.19, 1.92) Fatal Bleeding f 7 (0.07) 16 (0.15) 0.45 (0.19, 1.10) ICH 3 (0.03) 9 (0.08) 0.35 (0.09, 1.28) Non-intracranial g 4 (0.04) 7 (0.07) 0.59 (0.17, 2.02) There was a higher rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg than in patients receiving warfarin (6.6% vs 4.2%, respectively). The risk of major bleeds was similar with PRADAXA Capsules 150 mg and warfarin across major subgroups defined by baseline characteristics (see Figure 1), with the exception of age, where there was a trend toward a higher incidence of major bleeding on PRADAXA Capsules (hazard ratio 1.2, 95% CI: 1.0 to 1.5) for patients ≥ 75 years of age.

Figure 1 Adjudicated Major Bleeding by Baseline Characteristics Including Hemorrhagic Stroke Treated Patients Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors.

Apparent homogeneity or heterogeneity among groups should not be over-interpreted. Figure 1 Gastrointestinal Adverse Reactions Patients on PRADAXA Capsules 150 mg had an increased incidence of gastrointestinal adverse reactions (35% vs 24% on warfarin). These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).

Hypersensitivity Reactions In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in < 0.1% of patients receiving PRADAXA Capsules. Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism PRADAXA Capsules was studied in 4,387 patients in 4 pivotal, parallel, randomized, double-blind trials.

Three of these trials were active-controlled (warfarin) (RE-COVER, RE-COVER II, and RE-MEDY), and one study (RE-SONATE) was placebo-controlled. The demographic characteristics were similar among the 4 pivotal studies and between the treatment groups within these studies. Approximately 60% of the treated patients were male, with a mean age of 55.1 years.

The majority of the patients were white (87.7%), 10.3% were Asian, and 1.9% were black with a mean CrCl of 105.6 mL/min. Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).

RE-COVER and RE-COVER II studies compared PRADAXA Capsules 150 mg twice daily and warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Patients received 5-10 days of an approved parenteral anticoagulant therapy followed by 6 months, with mean exposure of 164 days, of oral only treatment; warfarin was overlapped with parenteral therapy.

Table 4 shows the number of patients experiencing bleeding events in the pooled analysis of RE-COVER and RE-COVER II studies during the full treatment including parenteral and oral only treatment periods after randomization. Table 4 Bleeding Events in RE-COVER and RE-COVER II Treated Patients Bleeding Events—Full Treatment Period Including Parenteral Treatment Note: MBE can belong to more than one criterion. a Patients with at least one MBE. b Bleeding site based on investigator assessment.

Patients can have more than one site of bleeding. c Confidence interval PRADAXA Capsules 150 mg twice daily N (%) Warfarin N (%) Hazard Ratio (95% CI) c Patients N=2,553 N=2,554 Major bleeding event a 37 (1.4) 51 (2.0) 0.73 (0.48, 1.11) Fatal bleeding 1 (0.04) 2 (0.1) Bleeding in a critical area or organ 7 (0.3) 15 (0.6) Fall in hemoglobin ≥ 2 g/dL or transfusion ≥ 2 units of whole blood or packed red blood cells 32 (1.3) 38 (1.5) Bleeding sites for MBE b Intracranial 2 (0.1) 5 (0.2) Retroperitoneal 2 (0.1) 1 (0.04) Intraarticular 2 (0.1) 4 (0.2) Intramuscular 2 (0.1) 6 (0.2) Gastrointestinal 15 (0.6) 14 (0.5) Urogenital 7 (0.3) 14 (0.5) Other 8 (0.3) 8 (0.3) Clinically relevant non-major bleeding 101 (4.0) 170 (6.7) 0.58 (0.46, 0.75) Any bleeding 411 (16.1) 567 (22.7) 0.70 (0.61, 0.79) The rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg in the full treatment period was 3.1% (2.4% on warfarin). The RE-MEDY and RE-SONATE studies provided safety information on the use of PRADAXA Capsules for the reduction in the risk of recurrence of deep vein thrombosis and pulmonary embolism.

RE-MEDY was an active-controlled study (warfarin) in which 1,430 patients received PRADAXA Capsules 150 mg twice daily following 3 to 12 months of oral anticoagulant regimen. Patients in the treatment studies who rolled over into the RE-MEDY study had a combined treatment duration of up to more than 3 years, with mean exposure of 473 days.

Table 5 shows the number of patients experiencing bleeding events in the study. Table 5 Bleeding Events in RE-MEDY Treated Patients PRADAXA Capsules 150 mg twice daily N (%) Warfarin N (%) Hazard Ratio (95% CI) c Note: MBE can belong to more than one criterion. a Patients with at least one MBE. b Bleeding site based on investigator assessment.

Patients can have more than one site of bleeding. c Confidence interval Patients N=1,430 N=1,426 Major bleeding event a 13 (0.9) 25 (1.8) 0.54 (0.25, 1.16) Fatal bleeding 0 1 (0.1) Bleeding in a critical area or organ 7 (0.5) 11 (0.8) Fall in hemoglobin ≥ 2 g/dL or transfusion ≥ 2 units of whole blood or packed red blood cells 7 (0.5) 16 (1.1) Bleeding sites for MBE b Intracranial 2 (0.1) 4 (0.3) Intraocular 4 (0.3) 2 (0.1) Retroperitoneal 0 1 (0.1) Intraarticular 0 2 (0.1) Intramuscular 0 4 (0.3) Gastrointestinal 4 (0.3) 8 (0.6) Urogenital 1 (0.1) 1 (0.1) Other 2 (0.1) 4 (0.3) Clinically relevant non-major bleeding 71 (5.0) 125 (8.8) 0.56 (0.42, 0.75) Any bleeding 278 (19.4) 373 (26.2) 0.71 (0.61, 0.83) In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg was 3.1% (2.2% on warfarin). RE-SONATE was a placebo-controlled study in which 684 patients received PRADAXA Capsules 150 mg twice daily following 6 to 18 months of oral anticoagulant regimen.

Patients in the treatment studies who rolled over into the RE-SONATE study had combined treatment duration up to 9 months, with mean exposure of 165 days. Table 6 shows the number of patients experiencing bleeding events in the study. Table 6 Bleeding Events in RE-SONATE Treated Patients PRADAXA Capsules 150 mg twice daily N (%) Placebo N (%) Hazard Ratio (95% CI) c Note: MBE can belong to more than one criterion. a Patients with at least one MBE. b Bleeding site based on investigator assessment.

Patients can have more than one site of bleeding. c Confidence interval Patients N=684 N=659 Major bleeding event a 2 (0.3) 0 Bleeding in a critical area or organ 0 0 Gastrointestinal b 2 (0.3) 0 Clinically relevant non-major bleeding 34 (5.0) 13 (2.0) 2.54 (1.34, 4.82) Any bleeding 72 (10.5) 40 (6.1) 1.77 (1.20, 2.61) In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg was 0.7% (0.3% on placebo). Clinical Myocardial Infarction Events In the active-controlled VTE studies, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA Capsules [20 (0.66 per 100 patient-years)] than in those who received warfarin [5 (0.17 per 100 patient-years)].

In the placebo-controlled study, a similar rate of nonfatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA Capsules [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)]. Gastrointestinal Adverse Reactions In the four pivotal studies, patients on PRADAXA Capsules 150 mg had a similar incidence of gastrointestinal adverse reactions (24.7% vs 22.7% on warfarin).

Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA Capsules 7.5% vs 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs 1.7%, respectively. Hypersensitivity Reactions In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA Capsules.

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery PRADAXA Capsules was studied in 5,476 patients, randomized and treated in two double-blind, active-controlled non-inferiority trials (RE-NOVATE and RE-NOVATE II). The demographic characteristics were similar across the two studies and between the treatment groups within these studies.

Approximately 45.3% of the treated patients were male, with a mean age of 63.2 years. The majority of the patients were white (96.1%), 3.6% were Asian, and 0.3% were black with a mean CrCl of 92 mL/min. Bleeding events for the RE-NOVATE and RE-NOVATE II studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or retroperitoneal bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells, requiring treatment cessation or leading to re-operation.

The RE-NOVATE study compared PRADAXA Capsules 75 mg taken orally 1-4 hours after surgery followed by 150 mg once daily, PRADAXA Capsules 110 mg taken orally 1-4 hours after surgery followed by 220 mg once daily and subcutaneous enoxaparin 40 mg once daily initiated the evening before surgery for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who had undergone hip replacement surgery. The RE-NOVATE II study compared PRADAXA Capsules 110 mg taken orally 1-4 hours after surgery followed by 220 mg once daily and subcutaneous enoxaparin 40 mg once daily initiated the evening before surgery for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who had undergone hip replacement surgery.

In the RE-NOVATE and RE-NOVATE II studies, patients received 28-35 days of PRADAXA Capsules or enoxaparin with median exposure of 33 days. Tables 7 and 8 show the number of patients experiencing bleeding events in the analysis of RE-NOVATE and RE-NOVATE II. Table 7 Bleeding Events in RE-NOVATE Treated Patients PRADAXA Capsules 220 mg N (%) Enoxaparin N (%) Patients N=1,146 N=1,154 Major bleeding event 23 (2.0) 18 (1.6) Clinically relevant non-major bleeding 48 (4.2) 40 (3.5) Any bleeding 141 (12.3) 132 (11.4) Table 8 Bleeding Events in RE-NOVATE II Treated Patients PRADAXA Capsules 220 mg N (%) Enoxaparin N (%) Patients N=1,010 N=1,003 Major bleeding event 14 (1.4) 9 (0.9) Clinically relevant non-major bleeding 26 (2.6) 20 (2.0) Any bleeding 98 (9.7) 83 (8.3) In the two studies, the rate of major gastrointestinal bleeds in patients receiving PRADAXA Capsules and enoxaparin was the same (0.1%) and for any gastrointestinal bleeds was 1.4% for PRADAXA Capsules 220 mg and 0.9% for enoxaparin.

Gastrointestinal Adverse Reactions In the two studies, the incidence of gastrointestinal adverse reactions for patients on PRADAXA Capsules 220 mg and enoxaparin was 39.5% and 39.5%, respectively. Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA Capsules 220 mg in 4.1% vs. 3.8% on enoxaparin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 0.6% vs 1.0%, respectively.

Hypersensitivity Reactions In the two studies, drug hypersensitivity (such as urticaria, rash, and pruritus) was reported in 0.3% of patients receiving PRADAXA Capsules 220 mg. Clinical Myocardial Infarction Events In the two studies, clinical myocardial infarction was reported in 2 (0.1%) of patients who received PRADAXA Capsules 220 mg and 6 (0.3%) of patients who received enoxaparin.

Pediatric Trials Treatment of VTE in Pediatric Patients The safety of PRADAXA in the treatment of VTE in pediatric patients was studied in one phase III trial (DIVERSITY). The DIVERSITY study was a randomized, open-label, active-controlled, parallel-group trial comparing PRADAXA with standard of care – SOC (vitamin K antagonists, low molecular weight heparin, or fondaparinux).

There were 266 pediatric patients who received study treatment, 176 patients treated with PRADAXA and 90 patients treated with SOC. Patients on PRADAXA received age- and weight-adjusted dosages of an age-appropriate formulation of PRADAXA (capsules, pellets, or oral solution) twice daily. Patients had a median age of 14 years (range: 0-17 years), 92% were white, and half the patients were male (50%).

Following at least 5 days of parenteral anticoagulant therapy, the median duration of treatment with PRADAXA was 85 days (range: 1-105). Patients with estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73 m² were excluded from the trial. Bleeding Data on adjudicated major bleeding, clinically relevant non-major (CRNM) bleeding and minor bleeding events, for the PRADAXA group and the SOC group in the DIVERSITY study, are reported in Table 9.

There was no statistically significant difference in the time to first major bleeding event. Table 9 Summary of All Adjudicated Bleeding Events During On-Treatment Period in DIVERSITY PRADAXA N (%) Standard of Care (SOC) N (%) 1 Major bleeding event if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.

Patients N=176 N=90 Major bleeding event 1 4 (2.3) 2 (2.2) Fatal bleeding 0 1 (1.1) Clinically relevant non-major bleeding 2 (1.1) 1 (1.1) Minor bleeding 33 (19) 21 (23) Major and clinically relevant non-major bleeding 6 (3.4) 3 (3.3) Any bleeding 38 (22) 22 (24) Site-specific bleeding rates were comparable between the two arms, with the exception of the rate of any gastrointestinal bleeds (5.7% in PRADAXA arm vs 1.8% in SOC arm). Gastrointestinal Adverse Reactions The incidence of gastrointestinal adverse reactions for patients on PRADAXA and SOC was 32% and 12%, respectively, with the following occurring in ≥ 5% of patients taking PRADAXA: dyspepsia (including term gastro-esophageal reflux disease, gastric pH decreased and esophagitis) in 9% (vs 2%), upper abdominal pain in 5% (vs 1%), vomiting in 8% (vs 2%), nausea 5% (vs 4%), and diarrhea 5% (vs 1%).

Reduction in Risk of Recurrence of VTE in Pediatric Patients The safety of PRADAXA in the reduction in the risk of recurrence of VTE in pediatric patients was studied in one open-label single-arm trial (Study 2). Study 2 enrolled patients who required further anticoagulation due to the presence of a clinical risk factor after completing the initial treatment for confirmed VTE (for at least 3 months) or after completing the DIVERSITY study and received PRADAXA until the clinical risk factor resolved, or up to a maximum of 12 months.

There were 213 pediatric patients treated with PRADAXA, in a similar fashion as in the DIVERSITY trial. Patients had a median age of 14 years (range: 0-18 years), 91% were white, and 55% of patients were male. Patients previously enrolled on DIVERSITY accounted for 43% of patients enrolled on Study 2 (29% from PRADAXA arm and 14% from SOC arm).

The median duration of treatment with PRADAXA in Study 2 was 42 weeks (range: 0-56 weeks), with 45% of patients completing the 12-month planned duration, 17% stopping due to resolution of VTE risk factors, 12% stopping due to failure to attain target dabigatran concentration and 6% had an adverse event leading to discontinuation. During the on-treatment period of Study 2, 3 patients (1.4%) had a major bleeding event, 3 patients (1.4%) had a clinically relevant non-major bleeding event, and 44 patients (20%) had a minor bleeding event.

The most common drug-related adverse reactions were dyspepsia (5%), epistaxis (3.3%), nausea (3.3%) and menorrhagia (2.8%). The adverse reaction profile in pediatric patients was generally consistent with that of adult patients.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of PRADAXA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders: Agranulocytosis, neutropenia, thrombocytopenia Gastrointestinal Disorders: Esophageal ulcer Immune System Disorders: Angioedema Renal and Urinary Disorders: Anticoagulant-related nephropathy Skin and Subcutaneous Tissue Disorders: Alopecia

Adverse reaction frequency tables (US label) US FDA label
Table 2 Summary of Treatment Exposure in RE-LY
PRADAXA Capsules 110 mg twice dailyPRADAXA Capsules 150 mg twice dailyWarfarin
Total number treated5,9836,0595,998
Exposure
> 12 months4,9364,9395,193
> 24 months2,3872,4052,470
Mean exposure (months)20.520.321.3
Total patient-years10,24210,26110,659
Table 3 Adjudicated Major Bleeding Events in Treated Patientsa
EventPRADAXA Capsules 150 mg N = 6,059 n (%/yearb)Warfarin N = 5,998 n (%/yearb)PRADAXA Capsules 150 mg vs Warfarin HR (95% CI)
aPatients during treatment or within 2 days of stopping study treatment. Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. bAnnual event rate per 100 pt-years = 100 * number of subjects with event/subject-years. Subject-years is defined as cumulative number of days from first drug intake to event date, date of last drug intake + 2, death date (whatever occurred first) across all treated subjects divided by 365.25. In case of recurrent events of the same category, the first event was considered. cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of ≥ 2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome. dIntracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds. eOn-treatment analysis based on the safety population, compared to ITT analysis presented in Section 14 Clinical Studies. fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding. gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.
Major Bleedingc350 (3.47)374 (3.58)0.97 (0.84, 1.12)
Intracranial Hemorrhage (ICH)d23 (0.22)82 (0.77)0.29 (0.18, 0.46)
Hemorrhagic Strokee6 (0.06)40 (0.37)0.16 (0.07, 0.37)
Other ICH17 (0.17)46 (0.43)0.38 (0.22, 0.67)
Gastrointestinal162 (1.59)111 (1.05)1.51 (1.19, 1.92)
Fatal Bleedingf7 (0.07)16 (0.15)0.45 (0.19, 1.10)
ICH3 (0.03)9 (0.08)0.35 (0.09, 1.28)
Non-intracranialg4 (0.04)7 (0.07)0.59 (0.17, 2.02)
Table 4 Bleeding Events in RE-COVER and RE-COVER II Treated Patients
Bleeding Events—Full Treatment Period Including Parenteral Treatment
Note: MBE can belong to more than one criterion. aPatients with at least one MBE. bBleeding site based on investigator assessment. Patients can have more than one site of bleeding. cConfidence interval
PRADAXA Capsules 150 mg twice daily N (%)Warfarin N (%)Hazard Ratio (95% CI)c
PatientsN=2,553N=2,554
Major bleeding eventa37 (1.4)51 (2.0)0.73 (0.48, 1.11)
Fatal bleeding1 (0.04)2 (0.1)
Bleeding in a critical area or organ7 (0.3)15 (0.6)
Fall in hemoglobin ≥ 2 g/dL or transfusion ≥ 2 units of whole blood or packed red blood cells32 (1.3)38 (1.5)
Bleeding sites for MBEb
Intracranial2 (0.1)5 (0.2)
Retroperitoneal2 (0.1)1 (0.04)
Intraarticular2 (0.1)4 (0.2)
Intramuscular2 (0.1)6 (0.2)
Gastrointestinal15 (0.6)14 (0.5)
Urogenital7 (0.3)14 (0.5)
Other8 (0.3)8 (0.3)
Clinically relevant non-major bleeding101 (4.0)170 (6.7)0.58 (0.46, 0.75)
Any bleeding411 (16.1)567 (22.7)0.70 (0.61, 0.79)
Table 5 Bleeding Events in RE-MEDY Treated Patients
PRADAXA Capsules 150 mg twice daily N (%)Warfarin N (%)Hazard Ratio (95% CI)c
Note: MBE can belong to more than one criterion. aPatients with at least one MBE. bBleeding site based on investigator assessment. Patients can have more than one site of bleeding. cConfidence interval
PatientsN=1,430N=1,426
Major bleeding eventa13 (0.9)25 (1.8)0.54 (0.25, 1.16)
Fatal bleeding01 (0.1)
Bleeding in a critical area or organ7 (0.5)11 (0.8)
Fall in hemoglobin ≥ 2 g/dL or transfusion ≥ 2 units of whole blood or packed red blood cells7 (0.5)16 (1.1)
Bleeding sites for MBEb
Intracranial2 (0.1)4 (0.3)
Intraocular4 (0.3)2 (0.1)
Retroperitoneal01 (0.1)
Intraarticular02 (0.1)
Intramuscular04 (0.3)
Gastrointestinal4 (0.3)8 (0.6)
Urogenital1 (0.1)1 (0.1)
Other2 (0.1)4 (0.3)
Clinically relevant non-major bleeding71 (5.0)125 (8.8)0.56 (0.42, 0.75)
Any bleeding278 (19.4)373 (26.2)0.71 (0.61, 0.83)
Table 6 Bleeding Events in RE-SONATE Treated Patients
PRADAXA Capsules 150 mg twice daily N (%)Placebo N (%)Hazard Ratio (95% CI)c
Note: MBE can belong to more than one criterion. aPatients with at least one MBE. bBleeding site based on investigator assessment. Patients can have more than one site of bleeding. cConfidence interval
PatientsN=684N=659
Major bleeding eventa2 (0.3)0
Bleeding in a critical area or organ00
Gastrointestinalb2 (0.3)0
Clinically relevant non-major bleeding34 (5.0)13 (2.0)2.54 (1.34, 4.82)
Any bleeding72 (10.5)40 (6.1)1.77 (1.20, 2.61)
Table 7 Bleeding Events in RE-NOVATE Treated Patients
PRADAXA Capsules 220 mg N (%)Enoxaparin N (%)
PatientsN=1,146N=1,154
Major bleeding event23 (2.0)18 (1.6)
Clinically relevant non-major bleeding48 (4.2)40 (3.5)
Any bleeding141 (12.3)132 (11.4)
Table 8 Bleeding Events in RE-NOVATE II Treated Patients
PRADAXA Capsules 220 mg N (%)Enoxaparin N (%)
PatientsN=1,010N=1,003
Major bleeding event14 (1.4)9 (0.9)
Clinically relevant non-major bleeding26 (2.6)20 (2.0)
Any bleeding98 (9.7)83 (8.3)
Table 9 Summary of All Adjudicated Bleeding Events During On-Treatment Period in DIVERSITY
PRADAXA N (%)Standard of Care (SOC) N (%)
1 Major bleeding event if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.
PatientsN=176N=90
Major bleeding event14 (2.3)2 (2.2)
Fatal bleeding01 (1.1)
Clinically relevant non-major bleeding 2 (1.1)1 (1.1)
Minor bleeding33 (19)21 (23)
Major and clinically relevant non-major bleeding 6 (3.4)3 (3.3)
Any bleeding38 (22)22 (24)

Monitoring parameters

  • CrCl before starting and when kidney function may decline (e.g., hypovolemia, nephrotoxic drugs); stop if acute kidney injury. Bleeding, hemoglobin. Reversal: idarucizumab in adults; hemodialysis has limited supporting data. Before surgery or invasive procedures, stop 1 to 2 days ahead if CrCl ≥50 mL/min, 3 to 5 days if CrCl <50; longer for major surgery or spinal/epidural procedures (label 2.8). Kidney
  • CrCl before and during therapy
  • Bleeding, hemoglobin
  • Before procedures: stop 1–2 days ahead (CrCl ≥50) or 3–5 days (CrCl <50) (label 2.8)
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary The limited available data on PRADAXA use in pregnant women are insufficient to determine drug-associated risks for adverse developmental outcomes. There are risks to the mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in the mother and fetus associated with the use of anticoagulants (see Clinical Considerations).

In pregnant rats treated from implantation until weaning, dabigatran increased the number of dead offspring and caused excess vaginal/uterine bleeding close to parturition at an exposure 2.6 times the human exposure. At a similar exposure, dabigatran decreased the number of implantations when rats were treated prior to mating and up to implantation (gestation Day 6).

Dabigatran administered to pregnant rats and rabbits during organogenesis up to exposures 8 and 13 times the human exposure, respectively, did not induce major malformations. However, the incidence of delayed or irregular ossification of fetal skull bones and vertebrae was increased in the rat (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Pregnancy confers an increased risk for thromboembolism that is higher for women with underlying thromboembolic disease and certain high-risk pregnancy conditions.

Published data describe that women with a previous history of venous thrombosis are at high risk for recurrence during pregnancy. Fetal/Neonatal adverse reaction Use of anticoagulants, including PRADAXA, may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding [see Warnings and Precautions (5.2)].

Labor or delivery All patients receiving anticoagulants, including pregnant women, are at risk for bleeding. PRADAXA use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider discontinuation or use of shorter acting anticoagulant as delivery approaches [see Warnings and Precautions (5.2, 5.3)].

Data Animal Data Dabigatran has been shown to decrease the number of implantations when male and female rats were treated at a dosage of 70 mg/kg (about 2.6 to 3.0 times the human exposure at MRHD of 300 mg/day based on area under the curve [AUC] comparisons) prior to mating and up to implantation (gestation Day 6). Treatment of pregnant rats after implantation with dabigatran at the same dose increased the number of dead offspring and caused excess vaginal/uterine bleeding close to parturition.

Dabigatran administered to pregnant rats and rabbits during organogenesis up to maternally toxic doses of 200 mg/kg (8 and 13 times the human exposure, respectively, at a MRHD of 300 mg/day based on AUC comparisons) did not induce major malformations, but increased the incidence of delayed or irregular ossification of fetal skull bones and vertebrae in the rat. Death of offspring and mother rats during labor in association with uterine bleeding occurred during treatment of pregnant rats from implantation (gestation Day 7) to weaning (lactation Day 21) with dabigatran at a dose of 70 mg/kg (about 2.6 times the human exposure at MRHD of 300 mg/day based on AUC comparisons).

Mechanism of action

12.1 Mechanism of Action Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics At recommended therapeutic doses, dabigatran etexilate prolongs the coagulation markers such as aPTT, ECT, TT, and dTT. INR is relatively insensitive to the exposure to dabigatran and cannot be interpreted the same way as used for warfarin monitoring. Figure 2 Adults The aPTT test provides an approximation of PRADAXA's anticoagulant effect.

The average time course for effects on aPTT, following approved dosing regimens in patients with various degrees of renal impairment is shown in Figure 2. The curves represent mean levels without confidence intervals; variations should be expected when measuring aPTT. While advice cannot be provided on the level of recovery of aPTT needed in any particular clinical setting, the curves can be used to estimate the time to get to a particular level of recovery, even when the time since the last dose of PRADAXA is not precisely known.

In the RE-LY trial, the median (10 th to 90 th percentile) trough aPTT in patients receiving the 150 mg dose was 52 (40 to 76) seconds. Figure 2 Average Time Course for Effects of Dabigatran on aPTT, Following Approved PRADAXA Dosing Regimens in Adult Patients with Various Degrees of Renal Impairment* *Simulations based on PK data from a study in subjects with renal impairment and PK/aPTT relationships derived from the RE-LY study; aPTT prolongation in RE-LY was measured centrally in citrate plasma using PTT Reagent Roche Diagnostics GmbH, Mannheim, Germany.

There may be quantitative differences between various established methods for aPTT assessment. The degree of anticoagulant activity can also be assessed by the ecarin clotting time (ECT). This test is a more specific measure of the effect of dabigatran than activated partial thromboplastin time (aPTT). In the RE-LY trial, the median (10 th to 90 th percentile) trough ECT in patients receiving the 150 mg dose was 63 (44 to 103) seconds.

In orthopedic hip surgery patients, maximum aPTT response (E max) to dabigatran and baseline aPTT were higher shortly after surgery than at later time points (e.g. ≥ 3 days after surgery). Pediatrics As in adults, there is a correlation between plasma dabigatran concentrations and the degree of its anticoagulant effect in pediatric patients with venous thromboembolism.

The parameters dTT and ECT increased in direct linear proportion to the plasma concentration of dabigatran, whereas aPTT prolongation increases in a nonlinear fashion with dabigatran plasma concentrations. Similar PK/PD relationships for aPTT, ECT, and dTT were observed across age groups of pediatric patients (ages 26 days to < 18 years) and between pediatric and adult patients with venous thromboembolism.

This similarity in PK/PD relationship suggests that similar exposure-response relationship is expected for dabigatran etexilate treatment across the pediatric age groups and adult patients. Cardiac Electrophysiology No prolongation of the QTc interval was observed with dabigatran etexilate at doses up to 600 mg.

Pharmacokinetics

Key PK parameters

Bioavailability3% to 7% (capsules must be swallowed whole)
Half-life12 to 17 hours (13 hours at CrCl ≥80)
Half-life in kidney failure (ESKD) kidney27 hours at CrCl 15–30 (label Table 10)
Protein bindingAbout 35%
Metabolism (CYP, transporters)Esterase hydrolysis of the prodrug; glucuronidation; not CYP
Active metabolitesDabigatran and its acyl glucuronides
Renal excretion kidneyRenal clearance 80% of total (IV)
Dialyzability kidneyYes (49% to 57% in 4 hours; label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Renal clearance of dabigatran is 80% of total clearance after intravenous administration.

The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.

Population pharmacokinetic simulation shows that the elimination half-life in pediatric patients is 12 to14 hours.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Dabigatran etexilate mesylate is absorbed as the dabigatran etexilate ester. The ester is then hydrolyzed, forming dabigatran, the active moiety. Dabigatran is metabolized to four different acyl glucuronides and both the glucuronides and dabigatran have similar pharmacological activity. Pharmacokinetics described here refer to the sum of dabigatran and its glucuronides.

Dabigatran displays dose-proportional pharmacokinetics in healthy adult subjects and adult patients in the range of doses from 10 to 400 mg. Given twice daily, dabigatran's accumulation factor in adults and pediatrics is approximately two. Absorption The absolute bioavailability of dabigatran following oral administration of dabigatran etexilate is approximately 3% to 7%.

Dabigatran etexilate is a substrate of the efflux transporter P-gp. After oral administration of dabigatran etexilate in healthy volunteers, C max occurs at 1-hour post-administration in the fasted state. Coadministration of PRADAXA with a high-fat meal delays the time to C max by approximately 2 hours but has no effect on the bioavailability of dabigatran; PRADAXA may be administered with or without food.

The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study. PRADAXA Capsules should therefore not be broken, chewed, or opened before administration. PRADAXA is available in capsules and oral pellets.

The approved indications and intended age groups are not the same. Oral absorption of dabigatran etexilate is formulation-dependent. At steady-state, dabigatran etexilate oral pellets show 37% higher relative bioavailability in healthy adults compared to dabigatran etexilate capsules based on a multiple-dose relative bioavailability study.

In addition, the relative bioavailability between the two dosage forms is age-dependent. The relative bioavailability observed in adults cannot be translated to pediatrics. Distribution Dabigatran is approximately 35% bound to human plasma proteins. The red blood cell to plasma partitioning of dabigatran measured as total radioactivity is less than 0.3.

The volume of distribution of dabigatran is 50 to 70 L. Elimination Dabigatran is eliminated primarily in the urine. Renal clearance of dabigatran is 80% of total clearance after intravenous administration. After oral administration of radiolabeled dabigatran, 7% of radioactivity is recovered in urine and 86% in feces. The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.

Population pharmacokinetic simulation shows that the elimination half-life in pediatric patients is 12 to14 hours. Metabolism After oral administration, dabigatran etexilate is converted to dabigatran. The cleavage of the dabigatran etexilate by esterase-catalyzed hydrolysis to the active principal dabigatran is the predominant metabolic reaction.

Dabigatran is not a substrate, inhibitor, or inducer of CYP450 enzymes. Dabigatran is subject to conjugation, forming pharmacologically active acyl glucuronides. Four positional isomers, 1-O, 2-O, 3-O, and 4-O-acylglucuronide exist, and each accounts for less than 10% of total dabigatran in plasma. Specific Populations Pediatric Patients The pharmacokinetics of dabigatran was characterized in two clinical studies (DIVERSITY and Study 2) following multiple doses in pediatric patients from birth to less than 18 years old.

In pediatric patients taking age- and weight-adjusted dosages of PRADAXA Capsules (aged 8-18 years), the observed geometric mean steady-state trough concentration was 97.9 ng/mL (63.7 to 151 ng/mL, 10 th to 90 th percentile) compared to the steady-state geometric mean trough concentration of 59.7 ng/mL (26.3 to 146 ng/mL, 10 th to 90 th percentile) observed in adult patients with DVT/PE. Renal Impairment An open, parallel-group, single-center study compared dabigatran pharmacokinetics in healthy adult subjects and adult patients with mild to moderate renal impairment receiving a single dose of PRADAXA Capsules 150 mg.

Exposure to dabigatran increases with severity of renal function impairment (Table 10). Similar findings were observed in the RE-LY, RE-COVER and RE-NOVATE II trials. Table 10 Impact of Renal Impairment on Dabigatran Pharmacokinetics Renal Function CrCl (mL/min) Increase in AUC Increase in C max t 1/2 (h) + Patients with severe renal impairment were not studied in RE-LY, RE-COVER and RE-NOVATE II.

Dosing recommendations in subjects with severe renal impairment are based on pharmacokinetic modeling [see Dosage and Administration (2.2, 2.4) and Use in Specific Populations (8.6)]. Normal ≥ 80 1× 1× 13 Mild 50-80 1.5× 1.1× 15 Moderate 30-50 3.2× 1.7× 18 Severe + 15-30 6.3× 2.1× 27 Hepatic Impairment Administration of PRADAXA Capsules in adult patients with moderate hepatic impairment (Child-Pugh B) showed a large inter-subject variability, but no evidence of a consistent change in exposure or pharmacodynamics.

Drug Interactions A summary of the effect of coadministered drugs on dabigatran exposure in healthy adult subjects is shown in Figures 3.1 and 3.2. In the orthopedic hip surgery patients, limited clinical data with P-gp inhibitors is available. Figure 3.1 Effect of P-gp Inhibitor or Inducer (rifampicin) Drugs on Peak and Total Exposure to Dabigatran (C max and AUC).

Shown are the Geometric Mean Ratios (Ratio) and 90% Confidence Interval (90% CI). The Perpetrator and Dabigatran Etexilate Dosage and Dosage Frequency are given as well as the Time of Perpetrator Dosage in Relation to Dabigatran Etexilate Dosage (Time Difference) Figure 3.2 Effect of Non-P-gp Inhibitor or Inducer, Other Drugs, on Peak and Total Exposure to Dabigatran (C max and AUC).

Shown are the Geometric Mean Ratios (Ratio) and 90% Confidence Interval (90% CI). The Perpetrator and Dabigatran Etexilate Dosage and Dosage Frequency are given as well as the Time of Perpetrator Dosage in Relation to Dabigatran Etexilate Dosage (Time Difference) In RE-LY, dabigatran plasma samples were also collected. The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.

Figure 3.1 Figure 3.2 Impact of Dabigatran on Other Drugs In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Dabigatran
PNF listing110 mg capsule
PNF listing150 mg capsule
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Pradaxa · Boehringer Ingelheim Pharmaceuticals Inc. [US FDA-approved label, version 48, June 25, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PhilHealth Advisory No. 2024-0026, PNF 8th ed. EML 2019 as of November 2, 2022 with newly approved medicines as of April 25, 2024; DOH-DC No. 2023-0282 (included 2023-06-22); https://www.philhealth.gov.ph/advisories/2024/PA2024-0026.pdf
  4. Boehringer Ingelheim Pharmaceuticals Inc. (2025). PRADAXA (dabigatran etexilate) capsules [Prescribing information; US FDA-approved label, NDA022512, set ID ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, version effective June 25, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9
  5. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
  6. Chan, K. E., Edelman, E. R., Wenger, J. B., Thadhani, R. I., & Maddux, F. W. (2015). Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation, 131(11), 972–979. https://doi.org/10.1161/CIRCULATIONAHA.114.014113

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .